DOCSLIB.ORG

Medical Faculty

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medical Faculty Subscription of Clinical Key Database for the year 2017 Medical Faculty - Gold Standard Drug Monographs SN Drug Name Collection On CK 1 A Thru Z Base 2013 2 A Thru Z Advantage Base 2013 3 A Thru Z Select Base 2013 4 Abacavir Base 09-05-14 5 Abacavir; Lamivudine, 3TC Base 08-11-13 6 Abacavir; Lamivudine, 3TC; Zidovudine, ZDV Base 08-11-13 7 Abarelix Base 04-04-14 8 Abatacept Base 2013 9 Abciximab Base 2013 10 Abetimus Base 2013 11 Abiraterone Base 30-01-14 12 AbobotulinumtoxinA Base 2013 13 Absorbable Gelatin Sponge Base 2013 14 Acamprosate Base 2013 15 Acarbose Base 09-05-14 16 Acebutolol Base 2013 17 Acerflex Base 2013 18 Acetaminophen Base 24-01-14 19 Acetaminophen; Aspirin, ASA; Caffeine Base 2013 Acetaminophen; Brompheniramine; Dextromethorphan; 20 Base 2013 Pseudoephedrine 21 Acetaminophen; Brompheniramine; Pseudoephedrine Base 2013 22 Acetaminophen; Butalbital Base 24-01-14 23 Acetaminophen; Butalbital; Caffeine Base 24-01-14 24 Acetaminophen; Butalbital; Caffeine; Codeine Base 24-01-14 25 Acetaminophen; Caffeine Base 2013 Acetaminophen; Caffeine; Chlorpheniramine; Hydrocodone; 26 Base 2013 Phenylephrine 27 Acetaminophen; Caffeine; Dihydrocodeine Base 24-01-14 28 Acetaminophen; Caffeine; Magnesium Salicylate; Base 2013 29 Acetaminophen;Phenyltoloxamine Caffeine; Phenyltoloxamine; Salicylamide Base 24-01-14 30 Acetaminophen; Chlorpheniramine Base 2013 31 Acetaminophen; Chlorpheniramine; Dextromethorphan Base 2013 32 Acetaminophen; Chlorpheniramine; Dextromethorphan; Base 2013 Acetaminophen;Phenylephrine Chlorpheniramine; Dextromethorphan; 33 Base 2013 Pseudoephedrine 34 Acetaminophen; Chlorpheniramine; Phenylephrine Base 2013 35 Acetaminophen; Chlorpheniramine; Phenylephrine; Base 2013 36 Acetaminophen;Phenyltoloxamine Chlorpheniramine; Pseudoephedrine Base 2013 37 Acetaminophen; Clemastine; Pseudoephedrine Base 2013 38 Acetaminophen; Codeine Base 2013 Page 1 of 71 Medical Faculty - Gold Standard Drug Monographs SN Drug Name Collection On CK 39 Acetaminophen; Dexbrompheniramine; Pseudoephedrine Base 2013 40 Acetaminophen; Dextromethorphan Base 2013 41 Acetaminophen; Dextromethorphan; Doxylamine Base 2013 42 Acetaminophen; Dextromethorphan; Doxylamine; Base 2013 43 Acetaminophen;Pseudoephedrine Dextromethorphan; Guaifenesin; Base 2013 44 Acetaminophen;Phenylephrine Dextromethorphan; Guaifenesin; Base 2013 45 Acetaminophen;Pseudoephedrine Dextromethorphan; Phenylephrine Base 2013 46 Acetaminophen; Dextromethorphan; Pseudoephedrine Base 2013 47 Acetaminophen; Dichloralphenazone; Isometheptene Base 2013 48 Acetaminophen; Diphenhydramine Base 2013 49 Acetaminophen; Diphenhydramine; Pseudoephedrine Base 2013 50 Acetaminophen; Guaifenesin; Phenylephrine Base 2013 51 Acetaminophen; Hydrocodone Base 14-02-14 52 Acetaminophen; Melatonin Base 2013 53 Acetaminophen; Oxycodone Base 28-03-14 54 Acetaminophen; Pamabrom Base 2013 55 Acetaminophen; Pamabrom; Pyrilamine Base 2013 56 Acetaminophen; Pentazocine Base 24-01-14 57 Acetaminophen; Phenyltoloxamine Base 2013 58 Acetaminophen; Propoxyphene Base 2013 59 Acetaminophen; Pseudoephedrine Base 2013 60 Acetaminophen; Tramadol Base 24-01-14 61 Acetazolamide Base 07-03-14 62 Acetic Acid, Glacial Base 2013 63 Acetic Acid; Hydrocortisone Base 2013 64 Acetic Acid; Oxyquinoline; Ricinoleic Acid Base 2013 65 Acetohexamide Base 09-05-14 66 Acetohydroxamic Acid Base 2013 67 Acetophenazine Base 2013 68 Acetylcholine Chloride Base 2013 69 Acetylcysteine Base 2013 70 Acidophilus with Pectin Base 2013 71 Acidulated Phosphate Fluoride Base 2013 72 Acitretin Base 2013 73 Acrivastine; Pseudoephedrine Base 2013 74 Acyclovir Base 14-04-14 75 Acyclovir; Hydrocortisone Base 06-09-13 76 Adalimumab Base 09-05-14 77 Adapalene Base 2013 78 Adapalene; Benzoyl Peroxide Base 2013 79 Adefovir Base 2013 80 ADEKs Base 2013 Page 2 of 71 Medical Faculty - Gold Standard Drug Monographs SN Drug Name Collection On CK 81 ADEKs Drops Base 2013 82 Adenosine Base 27-11-13 83 Adenovirus vaccine Base 2013 84 Ado-Trastuzumab emtansine Base 17-04-14 85 Advanced NatalCare Base 2013 86 Advanced-RF NatalCare Base 2013 87 Advera Base 2013 88 Afatinib Base 17-04-14 89 Aflibercept Base 2013 90 A-Free Prenatal Base 2013 91 Agalsidase Alfa Base 2013 92 Agalsidase Beta Base 2013 93 Airborne Effervescent Health Formula Base 2013 94 Airborne Jr. Effervescent Health Formula Base 2013 95 Airborne Sore Throat Gummi Lozenges Base 2013 96 Albendazole Base 10-01-14 97 Albiglutide Base 09-05-14 98 Albumin Base 2013 99 Albuterol Base 18-04-14 100 Albuterol; Ipratropium Base 14-04-14 101 Alcaftadine Base 2013 102 Alclometasone Base 2013 103 Aldesleukin, IL-2 Base 26-12-13 104 Alefacept Base 2013 105 Alemtuzumab Base 09-05-14 106 Alendronate Base 2013 107 Alendronate; Cholecalciferol Base 2013 108 Alfentanil Base 2013 109 Alfimeprase Base 2013 110 Alfuzosin Base 05-05-14 111 Alglucerase Base 2013 112 Alglucosidase alfa Base 2013 113 Alicaforsen Base 2013 114 Aliminase Base 2013 115 Aliskiren Base 08-11-13 116 Aliskiren; Amlodipine Base 22-11-13 117 Aliskiren; Amlodipine; Hydrochlorothiazide, HCTZ Base 08-11-13 118 Aliskiren; Hydrochlorothiazide, HCTZ Base 08-11-13 119 Aliskiren; Valsartan Base 09-05-14 120 Alitretinoin Base 2013 121 Alkavite Base 2013 122 Allbee C-800 Base 2013 Page 3 of 71 Medical Faculty - Gold Standard Drug Monographs SN Drug Name Collection On CK 123 AllBee Plus Vitamin C Base 2013 124 Allopurinol Base 2013 125 Almotriptan Base 2013 126 Aloe Polysaccharide; Iodoquinol Base 2013 127 Alogliptin Base 09-05-14 128 Alogliptin; Metformin Base 22-11-13 129 Alogliptin; Pioglitazone Base 09-05-14 130 Alosetron Base 19-09-13 131 Alpha lipoic acid Base 2013 132 Alpha-1-proteinase Inhibitor Base 2013 133 Alprazolam Base 28-03-14 134 Alprostadil Base 04-10-13 135 Alteplase, tPA Base 25-10-13 136 Altretamine Base 2013 137 Aluminum Acetate, Burow's Solution Base 2013 138 Aluminum Chloride Base 2013 139 Aluminum Hydroxide Base 08-11-13 140 Aluminum Hydroxide; Magnesium Carbonate Base 08-11-13 141 Aluminum Hydroxide; Magnesium Hydroxide Base 08-11-13 142 Aluminum Hydroxide; Magnesium Hydroxide; Simethicone Base 08-11-13 143 Aluminum Hydroxide; Magnesium Trisilicate Base 08-11-13 144 Alvimopan Base 2013 145 Amantadine Base 2013 146 Ambenonium Chloride Base 2013 147 Ambrisentan Base 19-09-13 148 Amcinonide Base 2013 149 Amediplase Base 2013 150 Amifostine Base 2013 151 Amikacin Base 09-05-13 152 Amiloride Base 09-05-14 153 Amiloride; Hydrochlorothiazide, HCTZ Base 2013 154 Aminate Fe Base 2013 155 Aminobenzoate Potassium Base 2013 156 Aminocaproic Acid Base 2013 157 Aminoglutethimide Base 2013 158 Aminolevulinic Acid Base 2013 159 Aminosalicylate sodium, Aminosalicylic acid Base 05-05-14 160 Aminosyn 10% Base 2013 161 Aminosyn 3.5% Base 2013 162 Aminosyn 3.5% M Base 2013 163 Aminosyn 5% Base 2013 164 Aminosyn 5% Sulfite-Free Base 2013 Page 4 of 71 Medical Faculty - Gold Standard Drug Monographs SN Drug Name Collection On CK 165 Aminosyn 7% Base 2013 166 Aminosyn 7% with Electrolytes Base 2013 167 Aminosyn 7% with Electrolytes Sulfite-Free Base 2013 168 Aminosyn 8.5% Base 2013 169 Aminosyn 8.5% Sulfite-Free Base 2013 170 Aminosyn 8.5% with Electrolytes Sulfite-Free Base 2013 171 Aminosyn II 10% Sulfite-Free Base 2013 172 Aminosyn II 10% with Electrolytes Base 2013 173 Aminosyn II 3.5% Base 2013 174 Aminosyn II 5% Base 2013 175 Aminosyn II 7% Base 2013 176 Aminosyn II 8.5% Base 2013 177 Aminosyn 10% Sulfite-Free Base 2013 178 Aminosyn 3.5% M Sulfite-Free Base 2013 179 Aminosyn 3.5% Sulfite-Free Base 2013 180 Aminosyn 7% Sulfite-Free Base 2013 181 Aminosyn 8.5% with Electrolytes Base 2013 182 Aminosyn -HBC 7% Base 2013 183 Aminosyn -HBC 7% Sulfite-Free Base 2013 184 Aminosyn II Base 2013 185 Aminosyn II 10% Base 2013 186 Aminosyn II 3.5% in Dextrose 25% Base 2013 187 Aminosyn II 8.5% Sulfite-Free Base 2013 188 Aminosyn -PF 10% Base 2013 189 Aminosyn -RF 5.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 6,692,728 B2 Weipert Et Al
    USOO6692728B2 (12) United States Patent (10) Patent No.: US 6,692,728 B2 Weipert et al. (45) Date of Patent: Feb. 17, 2004 (54) POLYESTERS BASED ON HYDROXY FATTY (52) U.S. Cl. ......................... 424/59; 424/497; 424/489; ACDS AND LOWER HYDROXY ALKYL 424/70.11; 424/78.37; 424/78.08; 514/785; ACDS AND USES THEREOF 560/171; 560/172; 560/176; 560/183; 525/400 (58) Field of Search .......................... 424/59, 497, 489, (75) Inventors: Paul David Weipert, High Point, NC 424/70.11, 78.37; 514/785; 560/172,176, (US); Bharat B. Desai, Spartanburg, 183; 525/400 SC (US) (73) Assignee: Ethox Chemicals LLC, Greenville, SC ") References Cited (US) U.S. PATENT DOCUMENTS ( c: ) Notice: Subject to any disclaimer, the term of this 5,502,116 A 3/1996 Noda ......................... 525/415 patent is extended or adjusted under 35 5,614,576 A * 3/1997 Rutherford et al. ......... 524/270 U.S.C. 154(b) by 0 days. 5,851,937 A * 12/1998 Wu et al. ................... 442/394 * cited by examiner (21) Appl. No.: 10/388,426 (22) Filed: Mar 17, 2003 Primary Examiner Sabiha Qazi 9 (74) Attorney, Agent, or Firm-Isaac A. Angres (65) Prior Publication Data (57) ABSTRACT US 2003/0175222 A1 Sep. 18, 2003 The present invention provides biodegradable polyesters Related U.S. Application Data based on lower hydroxy acids and hydroxy fatty acids. The resulting polyesters are useful as cosmetic vehicles for (62) Division of application No. 09/805,894, filed on Mar. 15, Sunscreens, skin lotions and by themselves are also useful as 2001, now Pat.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Assessment Report on Ricinus Communis L., Oleum Final
    2 February 2016 EMA/HMPC/572973/2014 Committee on Herbal Medicinal Products (HMPC) Assessment report on Ricinus communis L., oleum Final Based on Article 10a of Directive 2001/83/EC as amended (well-established use) Herbal substance(s) (binomial scientific name Ricinus communis L., oleum (castor oil) of the plant, including plant part) Herbal preparation Fatty oil obtained from seeds of Ricinus communis L. by cold expression Pharmaceutical forms Herbal preparation in liquid or solid dosage forms for oral use Rapporteur C. Purdel Peer-reviewer B. Kroes 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2016. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ................................................................................................................... 2 1. Introduction ....................................................................................................................... 4 1.1. Description of the herbal substance(s), herbal preparation(s) or combinations thereof .. 4 1.2. Search and assessment methodology ..................................................................... 6 2. Data on medicinal use ........................................................................................................ 6 2.1. Information about products on the market .............................................................
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Castor Oil Induces Laxation and Uterus Contraction Via Ricinoleic Acid Activating Prostaglandin EP3 Receptors Sorin Tunarua, Till F
    Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin EP3 receptors Sorin Tunarua, Till F. Althoffa, Rolf M. Nüsingb, Martin Dienerc, and Stefan Offermannsa,d,1 aDepartment of Pharmacology, Max-Planck-Institute for Heart and Lung Research, 61231 Bad Nauheim, Germany; dMedical Faculty, bInstitute for Clinical Pharmacology, J. W. Goethe University Frankfurt, 60590 Frankfurt, Germany; and cInstitute for Veterinary Physiology, Justus Liebig University, 35392 Giessen, Germany Edited by John H. Exton, Vanderbilt University School of Medicine, Nashville, TN, and approved April 25, 2012 (received for review January 30, 2012) Castor oil is one of the oldest drugs. When given orally, it has by the enteric nervous system or are direct effects on intestinal a laxative effect and induces labor in pregnant females. The smooth muscle remained unclear. effects of castor oil are mediated by ricinoleic acid, a hydroxylated The present study was undertaken to elucidate the molecular fatty acid released from castor oil by intestinal lipases. Despite the mechanism underlying the biological effect of castor oil-derived wide-spread use of castor oil in conventional and folk medicine, ricinoleic acid. Based on cellular signaling studies and an siRNA the molecular mechanism by which ricinoleic acid acts remains screening approach, we identified prostaglandin E2 receptors as unknown. Here we show that the EP3 prostanoid receptor is spe- targets of ricinoleic acid and show that the EP3 receptor medi- cifically activated by ricinoleic acid and that it mediates the phar- ates the effects of castor oil on the motility of the uterus and macological effects of castor oil. In mice lacking EP3 receptors, the the intestine.
    [Show full text]
  • Medicinal Chemistry Unit
    JAIPUR COLLEGE OF PHARMACY, JAIPUR B.PHARMACY, SECOND YEAR, FOURTH SEMESTER MEDICINAL CHEMISTRY-I Prepared by: Mrs. Nisha Dhir UNIT-III Cholinergic and Anticholinergic Drug The nervous system is divided into the somatic nervous system, which controls organs under voluntary control (mainly muscles) and the autonomic nervous system (ANS) which regulates individual organ function and homeostasis, and for the most part is not subject to voluntary control. The autonomic nervous system is also known as the visceral or automatic system. The ANS is predominantly an efferent system transmitting impulses from the central nervous system (CNS) to peripheral organ systems. The autonomic nervous system consists of sensory neurons and motor neurons that innervates between the central nervous system (especially the hypothalamus and medulla oblongata) and various internal organs such as the : heart, lungs, viscera, glands (both exocrine and endocrine). Thus it is responsible for monitoring conditions in the internal environment and bringing about appropriate changes in them. The ANS is divided into two separate divisions called the parasympathetic and sympathetic systems, on the basis of anatomical and functional differences. Both of these systems consist of myelinated preganglionic fibres which make synaptic connections with unmyelinated postganglionic fibres, and it is these which then innervate the effector organ. These synapses usually occur in clusters called ganglia. The main nerves of the parasympathetic system are the tenth cranial nerve, the vagus nerve, which originate in the medulla oblongata. Other preganglionic parasympathetic neurons also extend from the brain as well as from the lower tip of the spinal cord. Each preganglionic parasympathetic neuron synapses with just a few postganglionic neurons, which are located near or in the effector organ, a muscle or major gland.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]